FDA rejects Merck’s Vioxx Successor
Today, Merck announced that the FDA rejected its request to market a successor to its withdrawn arthritis drug Vioxx in the U.S. The move was widely expected after a panel of FDA advisers two weeks ago voted 20-1 against approving the drug Arcoxia.
For the full article.
Bookmark: 
